CompletedPhase 2NCT00625443
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eisai Inc.
- Principal Investigator
- Pei-Ran Ho, MDEisai Inc.
- Intervention
- Blinded (placebo)(drug)
- Enrollment
- 53 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2009
Study locations (12)
- Pacific Cancer Medical Center, Inc, Anaheim, California, United States
- Comprehensive Blood and Cancer Center, Bakersfield, California, United States
- Davis, Posteraro and Wasser, MDs, LLP, Manchester, Connecticut, United States
- Florida Cancer Institute, New Port Richey, Florida, United States
- John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology, Chicago, Illinois, United States
- Cancer Care Center, Inc., New Albany, Indiana, United States
- Capitol Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States
- Kansas City Cancer Center, LLC, Kansas City, Missouri, United States
- Mount Sinai Medical Center, New York, New York, United States
- New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, United States
- Emerywood Oncology and Hematology, High Point, North Carolina, United States
- Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00625443 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation